The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.3% during the forecast period. Shift towards immunotherapies coupled with an increasing number of indication expansion trials is one of the primary growth stimulants for the market.
Current
market analysis reveals Revlimid and Opdivo as bestselling therapies in the
marketplace in 2017. However, a robust pipeline will uplift Opdivo’s sales,
while Revlimid’s patent expiration will lower its revenue share in the market
by 2027. Although Keytruda poses strong competition to Opdivo, especially after
bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is
expected to trail behind the latter by 2027.
Lifecycle
management strategies, including the expansion of approved indications and
development of combination therapies, underline competitive dynamics in the
global blockbuster oncology brands market. Collaborative agreements signed by
participating companies facilitate development, commercialization, and regional
expansion of products. Such strategies not only enable players to gain easy
access into new markets but also allow them to leverage the scientific and
technological expertise of their collaborative partner.
For more info visit here: https://www.grandviewresearch.com/industry-analysis/blockbuster-oncology-brands-market
Further key
findings from the report suggest:
- North America
dominated the global arena in 2017, with approximately 65.0% share. The
region is likely to maintain its position through 2027
- In terms of
revenue, the lung cancer segment is estimated to expand at a CAGR of over
9.0% during the forecast period
- The multiple
myeloma segment held more than 30.0% of the market revenue in 2017 and is
anticipated to lose its position to lung cancer by 2027
- Europe is
projected to experience modest growth during the forecast period due to
delays in cost-effectiveness analysis, carried out by health technology
assessment bodies, slowing approval process and lowering reimbursement
- Some of the
key companies present in the market are Tesaro, Inc.; Merck &Co.;
Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.
Grand View Research has
segmented the global blockbuster oncology brands market on the basis of brands,
indication, and region:
Blockbuster
Oncology Brands Outlook (Revenue, USD Million, 2015 - 2027)
- Opdivo
- Keytruda
- Perjeta
- Ibrance
- Tecentriq
- Gazyva
- Zejula
- Tagrisso
- Darzalex
- Imbruvica
- Revlimid
Blockbuster
Oncology Brands Indication Outlook (Revenue, USD Million, 2015 - 2027)
- Lung cancer
- Breast cancer
- Multiple myeloma
- Lymphoma
- Others
Blockbuster
Oncology Brands Regional Outlook (Revenue, USD Million, 2015 - 2027)
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- Italy
- Spain
- France
- Switzerland
- Poland
- Denmark
- Asia Pacific
- China
- Japan
- India
- Australia
- New Zealand
- Philippines
- Indonesia
- Hong Kong
- Singapore
- South Korea
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Saudi Arabia
- Israel
- Turkey
Request a Sample Copy @ https://www.grandviewresearch.com/industry-analysis/blockbuster-oncology-brands-market/request/rs1
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment